BioActor signs Nestlé bone health deal

8 May 2015

BioActor is to collaborate with Nestlé Health Science on the development of nutritional products containing Bonolive, a health ingredient based on olive polyphenols, targeting bone health. Bonolive has, according to the company, been shown to stimulate osteoblast – bone producing cell – activity in a 12 month clinical study. The results of this study were […]

BioActor signs Nestlé bone health deal

anatomy-shoulder-bone-white-background-41167265BioActor is to collaborate with Nestlé Health Science on the development of nutritional products containing Bonolive, a health ingredient based on olive polyphenols, targeting bone health.

Bonolive has, according to the company, been shown to stimulate osteoblast – bone producing cell – activity in a 12 month clinical study. The results of this study were recently published in the Journal of Nutrition, Health & Aging. Bonolive has further shown in a pharmacokinetics study to have excellent bioavailability and to improve serum antioxidant status in healthy subjects.

“We are excited to work together with Nestlé Health Science,” said Hans van der Saag, Managing Director and founder of BioActor. “This collaboration first of all aims to strengthen scientific evidence for the benefits of Bonolive. With our combined capabilities I am confident that we will develop novel applications addressing well defined nutritional requirements, based on the newest scientific insights.”